Alpha-1A adrenergic receptor activation increases inhibitory tone in CA1 hippocampus.
Kristin L Hillman, Saobo Lei, Van A Doze, James E Porter
Index: Epilepsy Res. 84(2-3) , 97-109, (2009)
Full Text: HTML
Abstract
The endogenous catecholamine norepinephrine (NE) exhibits anti-epileptic properties, however it is not well understood which adrenergic receptor (AR) mediates this effect. The aim of this study was to investigate alpha(1)-adrenergic receptor activation in region CA1 of the hippocampus, a subcortical structure often implicated in temporal lobe epilepsies. Using cell-attached and whole-cell recordings in rat hippocampal slices, we confirmed that selective alpha(1)-AR activation increases action potential firing in a subpopulation of CA1 interneurons. We found that this response is mediated via the alpha(1A)-AR subtype, initiated by sodium influx, and appears independent of second messenger signaling. In CA1 pyramidal cells, alpha(1A)-AR activation decreases activity due to increased pre-synaptic GABA and somatostatin release. Examination of post-synaptic receptor involvement revealed that while GABA(A) receptors mediate the majority of alpha(1A)-adrenergic effects on CA1 pyramidal cells, significant contributions are also made by GABA(B) and somatostatin receptors. Finally, to test whether alpha(1A)-AR activation could have potential therapeutic implications, we performed AR agonist challenges using two in vitro epileptiform models. When GABA(A) receptors were available, alpha(1A)-AR activation significantly decreased epileptiform bursting in CA1. Together, our findings directly link stimulation of the alpha(1A)-AR subtype to release of GABA and somatostatin at the single cell level and suggest that alpha(1A)-AR activation may represent one mechanism by which NE exerts anti-epileptic effects within the hippocampus.
Related Compounds
Related Articles:
2011-07-01
[Anal. Bioanal. Chem 400(10) , 3625-33, (2011)]
2009-01-01
[Auton. Autacoid Pharmacol. 29(1-2) , 25-31, (2009)]
2006-02-01
[Arch. Physiol. Biochem. 112(1) , 23-30, (2006)]
2007-08-13
[Eur. J. Pharmacol. 569(1-2) , 110-8, (2007)]
2006-09-01
[BJU Int. 98(3) , 651-5, (2006)]